within Pharmacolibrary.Drugs.ATC.N;

model N06AX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used for the treatment of major depressive disorder (MDD) and fibromyalgia. It is approved for use in several countries for fibromyalgia and in some regions for depression.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Shelton, RC (2019). Serotonin and Norepinephrine Reuptake Inhibitors. <i>Handbook of experimental pharmacology</i> 250 145–180. DOI:<a href=&quot;https://doi.org/10.1007/164_2018_164&quot;>10.1007/164_2018_164</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30838456/&quot;>https://pubmed.ncbi.nlm.nih.gov/30838456</a></p></li><li><p>Li, F, et al., &amp; Ho, J (2012). Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 40(9) 1723–1735. DOI:<a href=&quot;https://doi.org/10.1124/dmd.112.045120&quot;>10.1124/dmd.112.045120</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22653299/&quot;>https://pubmed.ncbi.nlm.nih.gov/22653299</a></p></li><li><p>Ruan, CJ, et al., &amp; de Leon, J (2016). Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers. <i>Clinical pharmacokinetics</i> 55(7) 889–896. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0355-2&quot;>10.1007/s40262-015-0355-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26663198/&quot;>https://pubmed.ncbi.nlm.nih.gov/26663198</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX17;
